Skip to main content

Table 4 Serious infections incidence rates according to different treatment phases

From: Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients

 

CYC induction

RTX induction

RTX maintenance

Other maintenance agents or off-therapy

n of events

21

7

9

25

Patient-years

108.6

61.75

162.93

551.07

Incidence (per 100 patient-years)

19.34

11.34

5.52

4.53

Incidence rate ratio (95% CI)

4.24 (2.35–7.61)

2.49 (0.99–5.57)

1.22 (0.54–2.55)

Ref

  1. CYC cyclophosphamide, RTX rituximab, CI confidence intervals